National HER2 proficiency test results using standardized quantitative controls: Characterization of laboratory failures

Archives of Pathology and Laboratory Medicine

Volumn 132, Issue 2, 2008, Pages 211-216

  Vani, Kodela ^a   Sompuram, Seshi R ^a,b   Fitzgibbons, Patrick ^c   Bogen, Steven A ^a,b  

^a Medical Discovery Partners LLC   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST JUDE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTIC METHOD; ANTIGEN RETRIEVAL; ARTICLE; BREAST CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; ONCOGENE NEU; QUALITY CONTROL; QUANTITATIVE ANALYSIS; STANDARDIZATION;

ARTIFACTS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DIAGNOSTIC ERRORS; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 38949121249     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst. 2002;94:852-854.
2. Roche P, Suman V, Jenkins R, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002;94:855-857.
3. Perez E, Suman V, Davidson N, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol. 2006;24:3032-3038.
4. Ellis I, Bartlett J, Dowsett M, et al. Best practice No 176: updated recommendations for HER2 testing in the UK. J Clin Pathol. 2004;57:233-237.
5. Zarbo RJ, Hammond MEH. Conference summary, Strategic Science symposium: Her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med. 2003;127:549-553.
6. Cell Markers and Cytogenetics Committees, College of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med. 2002;126:803-808.
7. Hanna W, O'Malley F. Updated recommendations from the HER2/neu consensus meeting. Curr Oncol. 2002;9(suppl 1):S18-S19.
8. Wolff A, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18-43.
9. Rhodes A, Jasani B, Anderson E, Dodson A, Balaton A. Evaluation of HER2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors. Anat Pathol. 2002;118:408-417.
10. Rhodes A, Jasani B, Couturier, J, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol. 2002;117:81-89.
11. Sompuram S, Vani K, Bogen S. A molecular model of antigen retrieval using a peptide array. Am J Clin Pathol. 2006;125:91-98.
12. Sompuram S, Vani K, Messana E, Bogen S. A molecular mechanism of formalin-fixation and antigen retrieval. Am J Clin Pathol. 2004;121:190-199.
13. Sompuram S, McMahon D, Vani K, Ramanathan H, Bogen S. A novel microscope slide adhesive for poorly adherent tissue sections. J. Histotechnol. 2003;26:1-7.
14. Sompuram S, Vani K, Wei L, Ramanathan H, Olken S, Bogen S. A water-stable protected isocyanate glass array substrate. Anal Biochem. 2004;326:55-68.
15. Sompuram S, Kodela V, Zhang K, et al. A novel quality control slide for quantitative immunohistochemistry testing. J Histochem Cytochem. 2002;50:1425-1434.